Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Tax Provisions (2021 - 2024)

Historic Tax Provisions for Prime Medicine (PRME) over the last 4 years, with Q2 2024 value amounting to -$134000.0.

  • Prime Medicine's Tax Provisions fell 53225.81% to -$134000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was -$134000.0, marking a year-over-year decrease of 33508.77%. This contributed to the annual value of -$279000.0 for FY2023, which is 7056.96% up from last year.
  • Per Prime Medicine's latest filing, its Tax Provisions stood at -$134000.0 for Q2 2024, which was down 53225.81% from $134000.0 recorded in Q1 2024.
  • Prime Medicine's 5-year Tax Provisions high stood at $1.4 million for Q4 2021, and its period low was -$2.4 million during Q3 2021.
  • Over the past 4 years, Prime Medicine's median Tax Provisions value was -$134000.0 (recorded in 2024), while the average stood at -$202727.3.
  • Data for Prime Medicine's Tax Provisions shows a peak YoY increase of 16633.66% (in 2024) and a maximum YoY decrease of 53225.81% (in 2024) over the last 5 years.
  • Over the past 4 years, Prime Medicine's Tax Provisions (Quarter) stood at $1.4 million in 2021, then crashed by 113.61% to -$186000.0 in 2022, then skyrocketed by 41.94% to -$108000.0 in 2023, then decreased by 24.07% to -$134000.0 in 2024.
  • Its Tax Provisions stands at -$134000.0 for Q2 2024, versus $134000.0 for Q1 2024 and -$108000.0 for Q3 2023.